BCL2 and acute myeloid leukemia: Just as continuous activation of NF-κB may activate anti-apoptotic proteins Bcl-2 and Bcl-xL, suppressing NF-κB activity may activate its pre-apoptotic signals, thus increasing chemotherapy sensitivity of AML [25].